Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans

Mayo Clinic Proceedings

Volumn 83, Issue 10, 2008, Pages 1187-1188

  Hurt, Richard D ^a   Hays, J Taylor ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABASINE; COTININE; NICOTINE; NORNICOTINE; ALKALOID; BIOLOGICAL MARKER;

BUERGER DISEASE; DEFENSE MECHANISM; DENIAL; DISEASE ASSOCIATION; GANGRENE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; NICOTINE REPLACEMENT THERAPY; RESIDENTIAL CARE; SMOKING CESSATION; TOBACCO DEPENDENCE; URINE LEVEL; ADULT; CHEMISTRY; MALE; MIDDLE AGED; NOTE; SMOKING; TOBACCO; URINE;

ADULT; ALKALOIDS; BIOLOGICAL MARKERS; HUMANS; MALE; MIDDLE AGED; SMOKING; THROMBOANGIITIS OBLITERANS; TOBACCO;

EID: 54049134767     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.10.1187-b     Document Type: Letter

References (6)

1. Geske JB, Calvin AD, McDonald FS. 37-year-old man with painful foot. Mayo Clin Proc. 2008;83(7):821-824.
2. Moyer TP, Charlson JR, Enger RJ, et al. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem. 2002;48(9):1460-1471.
3. Barker N. The tobacco factor in thrombo-angiitis obliterans. Proc Staff Meet Mayo Clin. 1931;6(2):65-68.
4. Cooper LT, Henderson SS, Ballman KV, et al. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's disease). Angiology. 2006;57(1):73-78.
5. Hooten WM, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo Clin Proc. 1998;73(6):529-532.
6. Hays JT, Wolter TD, Eberman KM, Croghan IT, Offord KP, Hurt RD. Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence. Mayo Clin Proc. 2001;76(2):124-133.